Oric Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 12, 2024

ORIC$8.82+3.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	June 30, 2024	December 31, 2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$49,831	$23,384
Short-term investments	236,575	184,803
Prepaid expenses and other current assets	8,193	4,410
Total current assets	294,599	212,597
Long-term investments	22,126	26,852
Property and equipment, net	2,878	2,862
Other assets	9,303	9,696
Total assets	$328,906	$252,007
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,309	$944
Accrued liabilities	17,230	19,514
Total current liabilities	19,539	20,458
Other long-term liabilities	6,967	7,461
Total liabilities	26,506	27,919
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at June 30, 2024 and December 31, 2023	—	—
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 67,672,303 and 54,865,553 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	7	6
Additional paid-in capital	794,550	658,751
Accumulated deficit	(491,901)	(434,927)
Accumulated other comprehensive (loss) income	(256)	258
Total stockholders' equity	302,400	224,088
Total liabilities and stockholders' equity	$328,906	$252,007

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.